Business Description
ISIN : US0926671043
Share Class Description:
SRTA: Class ATotal Employee Number:
601Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.35 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -1.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.37 | |||||
Beneish M-Score | -0.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.4 | |||||
3-Year EBITDA Growth Rate | 36.4 | |||||
3-Year EPS without NRI Growth Rate | 31.8 | |||||
3-Year FCF Growth Rate | -11.2 | |||||
3-Year Book Growth Rate | -5.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.46 | |||||
9-Day RSI | 70.27 | |||||
14-Day RSI | 65.93 | |||||
3-1 Month Momentum % | -11.03 | |||||
6-1 Month Momentum % | 14.67 | |||||
12-1 Month Momentum % | 21.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.64 | |||||
Quick Ratio | 2.64 | |||||
Cash Ratio | 0.5 | |||||
Days Sales Outstanding | 53.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.6 | |||||
Shareholder Yield % | 1.32 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 20.56 | |||||
Operating Margin % | -7.97 | |||||
Net Margin % | 15.71 | |||||
EBITDA Margin % | -1.61 | |||||
FCF Margin % | -19.34 | |||||
OCF Margin % | -14.08 | |||||
ROE % | 14.89 | |||||
ROA % | 12.74 | |||||
ROIC % | -8.89 | |||||
3-Year ROIIC % | 23.18 | |||||
ROC (Joel Greenblatt) % | -25.72 | |||||
ROCE % | -7.1 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.75 | |||||
Forward PE Ratio | 79.26 | |||||
Price-to-Owner-Earnings | 13.08 | |||||
PS Ratio | 2.03 | |||||
PB Ratio | 1.89 | |||||
Price-to-Tangible-Book | 4.7 | |||||
EV-to-EBIT | -24.97 | |||||
EV-to-EBITDA | -123.64 | |||||
EV-to-Revenue | 1.99 | |||||
EV-to-Forward-Revenue | 0.86 | |||||
EV-to-FCF | -10.29 | |||||
Price-to-GF-Value | 1.25 | |||||
| Price-to-Net-Current-Asset-Value | 7.86 | |||||
Earnings Yield (Greenblatt) % | -4 | |||||
FCF Yield % | -9.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SRTA
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Strata Critical Medical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 255.975 | ||
| EPS (TTM) ($) | 0.508 | ||
| Beta | 3.3162 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 47.53 | ||
| 14-Day RSI | 65.93 | ||
| 14-Day ATR ($) | 0.252137 | ||
| 20-Day SMA ($) | 5.656 | ||
| 12-1 Month Momentum % | 21.7 | ||
| 52-Week Range ($) | 3.85 - 6.5 | ||
| Shares Outstanding (Mil) | 88.47 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Strata Critical Medical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Strata Critical Medical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 08:00 | In 79 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 78 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:00 | 5.55 (+9.90%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 5.55 (+9.90%) | ||
| General meeting for 2026 | 2026-05-28 09:00 | 6.26 (+1.79%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:00 | 4.82 (-2.63%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 4.82 (-2.63%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 13:30 | 4.33 (+4.59%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-03 08:00 | 4.49 (+6.90%) | ||
| Annual report for 2025 | 2026-03-03 | 4.49 (+6.90%) |
Strata Critical Medical Inc Frequently Asked Questions
Guru Commentaries on NAS:SRTA
Strata Critical Medical is a high-quality logistics and services asset growing more than 20% organically while operating in an inefficient, fragmented industry. The company has a cash-rich balance sheet and enormous M&A opportunities ahead. Strata is benefiting from the unmet need for organs, which is driving significant changes in the rules governing the distribution of viable organs. With a pristine balance sheet and its position as the only publicly traded pure-play organ-transplant logistics and services company, Strata is well-positioned to consolidate an industry with many subscale operators. We believe EBITDA can grow at a CAGR of more than 30% over the next five years, meaning that, at today’s share price, we are paying less than three times our estimate of 2030 EBITDA.
Strata Critical Medical is a high-quality logistics and services asset growing more than 20% organically while operating in an inefficient, fragmented industry. The company has a pristine balance sheet with zero debt and $59 million in cash, positioning it well for consolidation opportunities. Strata is benefiting from the unmet need for organs, which is driving significant changes in organ distribution rules and expanding the donor pool. With a projected 30% CAGR in EBITDA over the next five years, the current valuation appears too low, suggesting potential for substantial returns on investment.
Press Release
Articles on Strata Critical Medical Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
